Update on Myelodysplastic Syndromes: New Approaches to Classification and Therapy

Seminars in Oncology

Volumn 31, Issue 2 SUPPL. 4, 2004, Pages 72-79

  Langston, Amelia A ^a,b   Walling, Radhika ^a   Winton, Elliott F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ARSENIC TRIOXIDE; CYTARABINE; DEXAMETHASONE; DNA METHYLTRANSFERASE; ERYTHROPOIETIN; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; INTERLEUKIN 11; LENALIDOMIDE; METHYLTRANSFERASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

CANCER GRADING; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS;

EID: 2342549266     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.02.013     Document Type: Conference Paper

References (70)

1. Bartram CR: Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:557-570, 1992
2. Rosenfeld C, List A: A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies. Leukemia 14:2-8, 2000
3. Hofmann WK, Koeffler HP: Important features of myelodysplastic syndrome. Int J Hematol 76:222-227, 2002 (suppl 2)
4. Hirai H: Molecular pathogenesis of MDS. Int J Hematol 76:213-21, 2002 (suppl 2)
5. Miyazato A, Ueno S, Ohmine K, et al: Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98:422-427, 2001
6. Hofmann WK, de Vos S, Komor M, et al: Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100:3553-3360, 2002
7. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
8. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
9. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
10. Williamson PJ, Kruger AR, Reynolds PJ, et al: Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87:743-745, 1994
11. Aul C, Gattermann N, Schneider W: Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma 16:247-262, 1995
12. Cheson BD, Bennett JM, Kantarjian H, et al: Myelodysplastic syndromes standardized response criteria: further definition. Blood 98:1985, 2001 (abstr)
13. Hellstrom-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67-71, 1995
14. Negrin RS, Stein R, Doherty K, et al: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87:4076-4081, 1996
15. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75, 1998
16. Negrin RS, Haeuber DH, Nagler A, et al: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36-43, 1990
17. Yoshida Y, Hirashima K, Asano S, et al: A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78:378-384, 1991
18. Greenberg P, Taylor K, Larson R, et al: Phase III multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood 82:196a, 1993 (suppl 1) (abstr)
19. Kurzrock R, Cortes J, Thomas DA, et al: Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 19:4165-4172, 2001
20. Raza A, Mundle S, Shetty V, et al: Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 63:265-278, 1996
21. Raza A: Evolving concepts in myelodysplastic syndromes. Cancer Treat Res 108:1-24, 2001
22. Albitar M, Manshouri T, Shen Y, et al: Myelodysplastic syndrome is not merely "preleukemia". Blood 100:791-798, 2002
23. Deeg HJ: Marrow stroma in MDS: Culprit or bystander? Leuk Res 26:687-688, 2002
24. Greenberg P: Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. Ann Rheum Dis 60:iii41-iii42, 2001 (suppl 3)
25. Raza A, Meyer P, Dutt D, et al: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958-965, 2001
26. Bowen DT, Denzlinger C, Brugger W, et al: Poor response rate to a continuous schedule of Amifostine therapy for "low/intermediate risk" myelodysplastic patients. Br J Haematol 103:785-787, 1998
27. Deeg HJ, Gotlib J, Beckham C, et al: Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 16:162-164, 2002
28. Raza A, Qawi H, Andric T, et al: Pentoxifylline, ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients: Malignancy. Hematology 5:275-284, 2000
29. Dredge K, Dalgleish AG, Marriott JB: Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 14331-335, 2003
30. List AF, Kurtin S, Glinsmann-Gibson B, et al: Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood 102:184a, 2003 (abstr)
31. List A, Beran M, DiPersio J, et al: Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 17:1499-1507, 2003
32. List A, Schiller GJ, Mason J, et al: Trisenox (arsenic trioxide, ATO) in patients with myelodysplastic syndromes (MDS): Preliminary findings in a phase II clinical study. Blood 100:790a, 2002 (abstr)
33. Raza A, Lisak LA, Tahir S, et al: Trilineag responses to arsenic trioxide (Trisenox) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2). Blood 100:795a, 2002
34. Kurzrock R, Kantarjian HM, Cortes JE, et al: Farnesyl-transferase inhibitor R115777 in myelodysplastic syndrome: Clinical and biologic activities in the phase I setting. Blood 102:4527-4534, 2003
35. Pinto A, Attadia V, Fusco A, et al: 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922-929, 1984
36. Issa JP, Baylin SB, Herman JG: DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11:S7-S11, 1997 (suppl 1)
37. Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the pl5(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990, 1998
38. Tien HF, Tang JH, Tsay W, et al: Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 112:148-154, 2001
39. Zagonel V, Lo Re G, Marotta G, et al: 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7:30-35, 1993 (suppl 1)
40. Silverman LR, Holland JF, Weinberg RS, et al: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7:21-29, 1993 (suppl 1)
41. Daskalakis M, Nguyen TT, Nguyen C, et al: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964, 2002
42. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440, 2002
43. Barrett J, Saunthararajah Y, Molldrem J: Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology? Semin Hematol 37:15-29, 2000
44. Kook H, Zeng W, Guibin C, et al: Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 29:1270-1277, 2001
45. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al: Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102:1314-1422, 1998
46. Molldrem JJ, Leifer E, Bahceci E, et al: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137:156-163, 2002
47. Saunthararajah Y, Nakamura R, Nam JM, et al: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100:1570-1574, 2002
48. Kochenderfer JN, Kobayashi S, Wieder ED, et al: Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100:3639-3645, 2002
49. Beran M, Kantarjian H, O'Brien S, et al: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473-2479, 1996
50. Beran M, Estey E, O'Brien S, et al: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17:2819-2830, 1999
51. Lee ST, Jang JH, Suh HC, et al: Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol 68:237-245, 2001
52. Guilhot F, Bouabdallah R, Desablens B, et al: Topotecan, cytosine arabinoside and G-CSF (TAG) versus idarubicin, cytosine arabinoside, and G-CSF in patients with myelodysplastic syndrome (MDS) or MDS in transformation: A randomized phase III study. Blood 100:98a, 2002 (abstr)
53. Sierra J, Perez WS, Rozman C, et al: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002
54. Anderson JE, Anasetti C, Appelbaum FR, et al: Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93:59-67, 1996
55. Castro-Malaspina H, Harris RE, Gajewski J, et al: Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002
56. Bensinger WI, Martin PJ, Storer B, et al: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175-181, 2001
57. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207, 2002
58. Deeg HJ, Shulman HM, Anderson JE, et al: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95:1188-1194, 2000
59. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997
60. Sandmaier BM, McSweeney P, Yu C, et al: Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol 27:78-81, 2000 (suppl 5)
61. McCarthy NJ, Bishop MR: Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist 5:487-496, 2000
62. Slavin S, Nagler A, Shapira M, et al: Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. Crit Rev Oncol Hematol 39:25-29, 2001
63. Champlin R, Khouri I, Anderlini P, et al: Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Huntingt) 17:94-107, 2003
64. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
65. McSweeney PA, Niederwieser D, Shizuru JA, et al: Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400, 2001
66. Chakraverty R, Peggs K, Chopra R, et al: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071-1078, 2002
67. Maris MB, Niederwieser D, Sandmaier BM, et al: HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102:2021-2030, 2003
68. Kroger N, Bornhauser M, Ehninger G, et al: Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82:336-342, 2003
69. Parker JE, Shafi T, Pagliuca A, et al: Allogeneic stem cell transplantation in the myelodysplastic syndromes; interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119:144-154, 2002
70. Rezvani K, Lalancette, Szydlo R: Non-myeloablative stem cell transplant in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease. Blood 96:2061, 2000 (suppl) (abstr)